Medtronic (NYSE:MDT) is a global medical technology leader that develops and manufactures a wide range of medical devices and therapies. The company recently announced its quarterly financial results, showing performance that exceeded market expectations and led to a positive stock reaction for the medical device stock.
On September 1, 2026, Medtronic reported an earnings per share (EPS) of $1.45, beating analyst estimates of $1.39. This stronger-than-expected Q3 earnings profit prompts the company to raise its financial outlook for the year, indicating management's confidence in its continued performance.
The company also announced revenue of $9.76 billion, which surpasses the consensus estimate of $9.55 billion. This robust revenue growth is driven by broad-based demand for its innovative medical products. As highlighted by Reuters, there is particularly strong demand for its heart devices used in complex cardiovascular procedures.
To support future growth, Medtronic is making significant strategic investments in its newer platforms. The company is allocating over $700 million into key areas like Heart Tech and Robotics, as highlighted by WSJ. This includes a major investment in a new robot surgeon to enhance its technological capabilities and drive innovation.
From a valuation standpoint, Medtronic has a price-to-earnings (P/E) ratio of 22.16. The P/E ratio is a key valuation metric that shows how much investors are willing to pay for each dollar of a company's earnings. The company also has a price-to-sales ratio of 3.09, providing further insight into its market valuation.
